Imaging synaptic density in the living human brain
The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo imaging of synaptic density is now possible using PET and [ 11 C]UCB-J - a radioligand that binds to the synaptic vesicle protein 2A (SV2A) 41 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [41]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
In the citing paper
“there was also good correlation between SV2A and the “gold standard” pre-synaptic density marker synaptophysin in western blot and confocal microscopy experiments”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“Thus, it was decided that SV2A can be used as an alternative to synaptophysin for quantification of synapse density”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“quantification of radiotracer binding to SV2A does correlate with measures of synaptic vesicle number [8,9,69,70] and expression of other pre-synaptic proteins classically used in postmortem and in vitro work (e.g., synaptophysin, synapsin).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · cited 2×
“2 × 10(14) synapses per liter of brain tissue, as reported for the female human brain (42), and two to five SV2A copies per vesicle (31, 36), it can be estimated that there are 154 to 385 vesicles per synapse.”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11), or schizophrenia (12, 13).”
BackgroundWiedenmann, B., & Franke, W. W. (1985) · Cell · doi:10.1016/s0092-8674(85)80082-9 · Cited by 1,428 · cited 1×
“SYN is themost abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33), because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins.”
BackgroundLoss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
Research works printed but not linked: 1
- 10.1097/01.wcb.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
Cited by
Items 401–500 of 592
Schrauwen, C., Halloin, N., Eetveldt, A. V., Laermans, Z., Vos, W. H. D., Jankovski, A., Verhoye, M., Staelens, S. G., Nicaise, C., & Bertoglio, D. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271236 · Cited by 2
“…vesicle glycoprotein 2A (SV2A), a protein present in the presynaptic vesicles and involved in neurotransmitter release ( 12 ), represents a promising noninvasive PET imaging target to estimate synaptic density in the entire central nervous system both preclinically and clinically ( 13 – 15 ).”
Hernández‐Martín, N., Balayeva, T., Naganawa, M., Asch, R., Huang, Y. H., Carson, R. E., Gallezot, J., & Cai, Z. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271207 · Cited by 3
Self-citationSynaptic density in the hippocampus of depressed patients: A quantitative electron microscopic study
Sebők-Tornai, A., Csabai, D., Szocsics, P., Gombás, P., Cobb, J. A., Mahajan, G., Stockmeier, C. A., & Czéh, B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111661 · Cited by 2
“This radioligand labels the synaptic vesicle glycoprotein 2 A (SV2A) and allows the in vivo imaging of nerve terminals, and by that it provides an indirect estimate of synaptic densities (Finnema et al., 2016; Howes et al., 2024).”
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Detection of Focal Lesions in Epilepsy with [ 18 F]UCB-H Synaptic Vesicle Protein 2A PET Imaging
Pakula, V., Dorneich, J. S., Frontzkowski, L. K., Bartos, L. M., Fearns, N., Roemer, S. N., Lindner, S., Zwergal, A., Kaufmann, E., Höglinger, G. U., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271505 · Cited by 2
“Compared with other SV2A tracers such as [ 11 C]UCB-J or [ 18 F]SynVesT-2, [ 18 F]UCB-H has been reported to exhibit lower af fi nity and slower kinetics ( 15 ).”
Sleep deprivation increases levels of the synaptic density marker SV2A in the human brain
Elmenhorst, D., Foerges, A. L., Gordji-Nejad, A., Elmenhorst, E., Kroll, T., Matusch, A., Beer, S., Neumaier, B., Krapf, P., Lerche, C., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003816 · Cited by 2
“[ 18 F]SynVesT-1 PET data acquisition and magnetic resonance (MR) were conducted on a 3 Tesla PET/MR system (BrainPET; Siemens Healthineers).”
InfluentialImaging biomarkers in neurodegenerative diseases: advances and challenges
Majumdar, S., Samaiya, P. K., Ahmed, S., & Prajapati, S. K. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1813588 · Cited by 2
“Moreover, research on synaptic PET ligands which target SV2A protein has shown that PET signals match histological measurements of synaptic density for [11C]UCB-J and other similar compounds (Finnema et al., 2016).”
Degroot, A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00002-3 · Cited by 2
Koohsari, S., Yang, Y., & Matuskey, D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_374 · Cited by 2
Self-citationMedicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future
Pijeira, M. S. O., Nunes, P. S. G., Chaviano, S. L., Diaz, A. M. A., DaSilva, J. N., Ricci‐Júnior, E., Alencar, L. M. R., Chen, X. S., & Santos‐Oliveira, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230818092634 · Cited by 2
PET Quantification and Kinetic Analysis
Carson, R. E., Naganawa, M., & Gallezot, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_12 · Cited by 4
Self-citationLi, J., Zou, R., Varrone, A., Nag, S., Halldin, C., & Ågren, H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00029 · Cited by 4
Importance of Visual Support Through Lipreading in the Identification of Words in Spanish Language
Gómez‐Vicente, V., Esquiva, G., Lancho, C., Benzerdjeb, K., Jeréz, A. A., & Ausó, E. (2024) · Language and Speech · doi:10.1177/00238309241270741 · Cited by 2
“In all cases, the diagnosis of the models (homoscedasticity and normality of the residuals) was fulfilled, implying the suitability of the final selected models (Finnema et al., 2016).”
Preclinical PET imaging of the developing fetus during pregnancy: Current state and future potential
Pearson, T. D., Bricault, S., Lin, Y.-S., Barusso, K. E., Bodangi, S., & Wey, H. (2025) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x251340510 · Cited by 2
“39 In pregnant NHPs, longitudinal quantification of SV2A availability in fetal brains could serve as a measure of synaptogenesis during neu-rodevelopment.”
Brain Mapping and Synapse Quantification In vivo: It's Time to Imaging
Acebes, Á. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2017.00017 · Cited by 2
“This scenario may change thanks to the recent work of Finnema and collaborators reporting the use of positron emission tomography (PET) to count synapses (Finnema et al., 2016).”
BackgroundInfluentialImpact de l’imagerie TEP métabolique et moléculaire dans les maladies neurodégénératives cognitives
Lagarde, J., Olivieri, P., Bottlaender, M., & Sarazin, M. (2021) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2021.03.011 · Cited by 2
Zeydan, B., & Kantarci, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_1 · Cited by 3
Vardalaki, D., Pham, T. L. D., Frosch, M. P., Cosgrove, G. R., Carter, B. S., Richardson, R. M., Cash, S. S., & Harnett, M. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-18207-3 · Cited by 3
Stephen, R. (2020) · UEF eRepo (University of Eastern Finland) · Cited by 7
Imaging synaptic microstructure and synaptic loss in vivo in early Alzheimer’s DiseasePreprint
Venkataraman, A. V., Bishop, C., Mansur, A., Rizzo, G., Lewis, Y. L., Kocagöncü, E., Lingford-Hughes, A. R., Huiban, M., Passchier, J., Rowe, J. B., et al. (2021) · medRxiv · doi:10.1101/2021.11.23.21266746 · Cited by 3
“image the distribution and abundance of SV2A as an index of synaptic density [18,28,29].”
BackgroundMethodInfluentialUncovering the link between synaptic density and mental illness through in vivo imaging
Smart, K. A., & Boileau, I. (2023) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.230033 · Cited by 2
Shatalina, E., Onwordi, E. C., Whitehurst, T., Whittington, A., Mansur, A., Arumuham, A., Marques, T. R., Gunn, R. N., Natesan, S., Rabiner, E. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614893 · Cited by 2
“[11C]UCB-J PET specifically binds the SV2A protein, which is ubiquitously expressed on vesicles across all synapse types [36, 37].”
BackgroundCorvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Applications of Neuroimaging Biomarkers in CNS Drug Development
Cole, P. E., & Einstein, S. G. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00009-6 · Cited by 2
Potential of [11C]UCB-J as a PET tracer for islets of Langerhans
Puuvuori, E., Rokka, J., Carlsson, P., Li, Z., Eriksson, J., & Eriksson, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-04188-6 · Cited by 1
Cini, N., Atasoy, O., Erdoğan, M. A., Yaprak, G., Eroglu, E., Şirin, C., Uyanıkgil, Y., & Erbaş, O. (2023) · International Journal of Radiation Research · doi:10.61186/ijrr.21.3.435 · Cited by 1
Biomarkers for Alzheimer's Disease: Early Diagnosis
Panwar, D., Sharma, P., Sharma, S., Malik, M., & Kaur, J. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch003 · Cited by 1
Burke, S. N., & Barnes, C. A. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0015 · Cited by 2
Wimberley, C., Alcaide-Corral, C. J., Morgan, T. E. F., MacAskill, M. G., Andrews, B., McErlain, H., Burianova, V. K., Sutherland, A. J., & Tavares, A. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01270-2 · Cited by 1
“The epilepsy drug levetiracetam binds to SV2A selectively and has been the basis for development of multiple radiotracers, the first of which, [ 11 C]UCB-J, was shown to correlate with ex vivo measures of SV2A in the non-human primate [1].”
Neuroscience Methods for Investigating Brain Plasticity
Verra, L., Renz, F. M., & Schuck, N. W. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197677131.013.24 · Cited by 1
Asch, R., Martin, N. H., García-Milian, R., Fowles, K., Dileone, R., Cai, Z., Liston, C. M., & Esterlis, I. (2025) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2025.09.021 · Cited by 2
Katiyar, D., & Manish, M. (2025) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2025.100126 · Cited by 2
The synthesis of [ 18 F]SynVesT-1 and [ 18 F]SynVesT-2 from enantioenriched boronic esters
Qin, M., Mishra, P. K., Hind, J., Fallis, I. A., & Tredwell, M. J. (2025) · Chemical Communications · doi:10.1039/d5cc05507e · Cited by 1
Nuclear Medicine: Essential Concepts and Applications
Malik, M. M. U. D., & Alqahtani, M. M. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813543125010004 · Cited by 1
Lien, C.-H., Vanderlinden, G., Casteele, T. V., Laroy, M., Cauwenberge, M. G. A. V., Vansteelandt, K., Koole, M. J. B., Peeters, R. R., Sunaert, S. G., Bouckaert, F., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-025-13613-z · Cited by 1
“Moreover, PET imaging with 11 C-UCB-J, enabling in vivo quantification of synaptic density, revealed lower synaptic density in regions vulnerable to tau pathology [18, 19].”
Redox‐Activated Probes Enable High‐Contrast Live Imaging of Native Postsynaptic Scaffolds
Huhn, C., Mille, C., Ho, S., Lützenkirchen, F. P., Khayenko, V., Hein, M., Werner, C. D., Kneussel, M., Hell, J. W., Specht, C. G., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202519933 · Cited by 1
Onwordi, E. C., Whitehurst, T., Shatalina, E., Mansur, A., Arumuham, A., Osugo, M., Marques, T. R., Jauhar, S., Mehrotra, R., Ranger, M., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02349-7 · Cited by 1
“Synaptic vesicle glycoprotein 2A (SV2A) is a protein expressed in synaptic terminals, and can be indexed in vivo using positron emission tomography (PET) as a marker of synaptic terminal density [34].”
InfluentialUribe, C., Narciso, L., Cho, S. S., Zilberman, M., Cote, C., Yu, L., Truong, J. T., Dickie, E. W., Nikolova, Y. S., Voineskos, A. N., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07818-1 · Cited by 1
“The best available proxy is the SV2A protein ubiquitously expressed in presynaptic termi - nals [ 5].”
Dose reduction for synaptic density PET imaging in Parkinson’s disease
Li, A., Naganawa, M., Honhar, P., Fontaine, K. M., Gravel, P., Matuskey, D., Carson, R. E., & Tang, J. (2026) · NeuroImage · doi:10.1016/j.neuroimage.2026.121853 · Cited by 2
Self-citationGravel, P., Gallezot, J., Fontaine, K. M., Matuskey, D., & Carson, R. E. (2026) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ae520a · Cited by 1
“Here we evaluate both within-subject and between-subject variability for multiple real Parkinson’s disease (PD) patients scanned with [ 11 C]UCB-J, a radioligand for synaptic vesicle glycoprotein 2A (SV2A), a marker for synaptic density (Finnema et al 2016).”
Self-citationHigh-resolution in utero SV2A PET imaging of the nonhuman primate brain using the NeuroEXPLORER
Mehta, S., Sun, H., Micali, N., Holden, D., Fowles, K., Rossano, S. M., Zhang, J., Ma, C., Han, P. C., Lee, W., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261429044 · Cited by 1
Self-citationDetecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach
Agnorelli, C., Peill, J. M., Sawicka, G., Kurtin, D. L., Shatalina, E., Ahmad, K., Wall, M. B., Rua, C., Godfrey, K., Ertl, N., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261431447 · Cited by 1
“10 13 However, despite considerable animal research indicating that ketamine’s rapid and sustained antidepressant effects stem from increased structural and functional neuroplasticity, confirming these findings in the living human brain presents significant challenges.”
Synaptic loss in alcohol use disorder: clinical and mechanistic insights from a PET imaging study
Royse, S. K., & Narendran, R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204460 · Cited by 1
Woelfle, S., Schön, M., Pedro, M. T., Wagner, J., Shiban, E., Hong, B., Tsoy, Y., & Boeckers, T. M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107503 · Cited by 1
Yokokura, M., Tamayama, T., Kameno, Y., Iwabuchi, T., Goto, T., Murata, I., Harada, T., Ichinohe, N., Ouchi, Y., & Yamasue, H. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03812-z · Cited by 1
PET Imaging of T Cells: Target Identification and Feasibility Assessment
Auberson, Y. P., Briard, E., Rudolph, B., Kaupmann, K., Smith, P. A., & Oberhauser, B. (2018) · ChemMedChem · doi:10.1002/cmdc.201800241 · Cited by 1
Synaptic Vesicle Glycoprotein 2A and Epilepsy
Hanaya, R., Hosoyama, H., & Arita, K. (2018) · てんかん研究 · doi:10.3805/jjes.36.3 · Cited by 1
Brain PET Poster Sessions PP01-M01 to PP02-N07
Lange, D., Tejada, I. M., xiong, M., Hillebrand, B., Noergaard, M., Baerentzen, S., Shalgunov, V., Herth, M. M., Svarer, C., & Palner, M. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19851018 · Cited by 1
Frontiers in Neuroscience Imaging
Thaker, A. A., Chien, A. L., & Dubroff, J. G. (2020) · PET Clinics · doi:10.1016/j.cpet.2020.09.014 · Cited by 2
Yun, J., & Kim, Y. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_14 · Cited by 1
Hagler, D. J., Thompson, W. K., Chen, C., Reuter, C., Akshoomoff, N. A., & Brown, T. T. (2022) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2022.101086 · Cited by 1
“For example, studies of synaptic density using several methods have been conducted in typically developing young and older adults, adults with neuropsychiatric illness, and adults with HIV and epilepsy (Alonso-Nanclares et al., 2008; Everall et al., 2006; Finnema et al., 2016; Hahn et al., 2009).”
Cognitive reserve in multiple sclerosis
Pashkovskaya, D. V., Alifirova, V. M., & Kamenskikh, E. M. (2022) · Russian neurological Journal · doi:10.30629/2658-7947-2022-27-2-14-21 · Cited by 1
Koole, M. J. B., Lacroix, B. D., Tang, C., Chanteux, H., Maguire, R. P., & Laere, K. V. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101133 · Cited by 2
“PET based SV2A occupancy estimates have already been reported using [ 11 C]-UCB-J as PET radioligand which has shown high af fi nity and speci fi city for SV2A, and optimal pharmacokinetic properties with no evidence of brain penetrating radiometabolites (Finnema, 2016).”
Synaptic PET Imaging in Neurodegeneration
Chen, M., Matuskey, D., Finnema, S. J., & Carson, R. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_10 · Cited by 1
Self-citationIn vivo neuropil density from anatomical MRI and machine learning
Akif, A., Staib, L. H., Hermán, P., Rothman, D. L., Yu, Y., & Hyder, F. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae200 · Cited by 1
Evaluation of [11C]UCB-A positron emission tomography in human brains
Xiong, M., Lubberink, M., Appel, L., Fang, X. T., Danfors, T., Kumlien, E., & Antoni, G. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01117-2 · Cited by 1
“The three compounds underwent initial animal evaluations before [ 11 C]UCB-J and [ 18 F]UCB-H progressed to human studies [4, 9–11].”
BackgroundMethodResultInfluentialHalff, E. F., Côtel, M.-C., Natesan, S., McQuade, R., Ottley, C. J., Srivastiva, D. P., Howes, O. D., & Vernon, A. C. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.14.033944 · Cited by 1
Gonçalves, A. J., Alotaibi, M., Carlin, A., Chen, Y., Wong, C., Djoukhadar, I., Krokos, G., Jackson, A., Coope, D. J., & Asselin, M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211061050 · Cited by 1
The biology of schizophrenia as a neurodevelopmental disorder
van Berlekom, A. B. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1269 · Cited by 1
Nolan, G., Holland, N., Yang, S. W., Dall‘O’, G. M., Chen, Q., Allinson, K. S. J., Savulich, G., Halliday, K., Naessens, M., Hong, Y. T., et al. (2026) · medRxiv · doi:10.64898/2026.06.02.26354325 · Cited by 1
Abuhamdia, Z. A. (2016) · Journal of Literature, Languages and Linguistics
Mitterauer, B. (2016) · International Journal of Brain Disorders and Treatment · doi:10.23937/2469-5866/1510015
The postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox
Kvartsberg, H. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 2
Comorbid Metabolic Syndrome and Prodromal Alzheimer's Disease in a Rat Model
Ivanova, N. A. (2019) · Scholarship@Western (Western University)
A Review of Pre-Clinical Studies for the Treatment of Neonatal Brain Injury
Kolb, B. E., & Williams, P. T. J. A. (2020) · Neurology and Neurobiology · doi:10.31487/j.nnb.2020.01.07
“Modern neuroimaging technology such as twophoton imaging has allowed researchers to observe changes in spines as they occur in laboratory rodents [18].”
BackgroundHuang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6 · Cited by 1
Self-citationHamilton, J. (2020) · Scholarship@Western (Western University) · Cited by 2
The Influence of Neuropsychological Processes on Criminal Actions
Foley, D. (2019) · University of Huddersfield Repository (University of Huddersfield)
Dendritic spine remodeling and aging
Boros, B. D., & Herskowitz, J. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817990-1.00022-6
New PET radiopharmaceuticals for imaging CNS diseases
Brumberg, J., & Varrone, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00002-8
Mansur, A. (2020) · Spiral (Imperial College London) · doi:10.25560/84574 · Cited by 1
La poesía es cuestión de tiempo
García, F. J. Q. (2000) · La Página
Khalil, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47829-6_1239-1
Caviness, J. N. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737231678.793570128
Principles of PET and Its Role in Understanding Drug Delivery to the Brain
Syvänen, S., Gunn, R. N., & Zhang, L. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_11 · Cited by 1
Khalil, A. A. (2022) · Springer eBooks · doi:10.1007/978-3-319-55065-7_1239
Molecular imaging beyond dopamine and serotonin in familial and idiopathic Parkinson’s disease
Wilson, H., Terry, A., & Politis, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821651-4.00002-6
Efeito do exercício físico na nocicepção induzida no modelo de doença de Pakirson em ratos.
Binda, K. H. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2020.tde-06012021-154244
He, Y., & Xie, F. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/ksjb6678
Lagarde, J. (2022) · theses.fr (ABES) · doi:10.70675/3cc93d32z274fz4079zb037z280b6cc59858 · Cited by 1
Rollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2025) · eLife · doi:10.1101/2024.06.14.599047
“…data for a density of synaptic complexes in humans are still rare (but see Marco and DeFelipe, 1997 ; Tang et al., 2001 ; DeFelipe et al., 1999 ; DeFelipe et al., 2002 ; Alonso-Nanclares et al., 2008 ; Blazquez-Llorca et al., 2013 ; Finnema et al., 2016 ; Cano et al., 2021 ; Cano et al., 2023 ).”
Challenges and constraints of using radiology images to diagnose COVID-19
Mishra, S., Kar, B., Dehury, B., Pati, S., & Badar, M. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95374-0.00016-6
Compressed representation of brain genetic transcription
Ruffle, J. K., Watkins, H., Gray, R., Hyare, H., de Schotten, M. T., & Nachev, P. (2024) · Human Brain Mapping · doi:10.1002/hbm.26795
“Third, we acquired open-source PET imaging of synaptic vesicle glycoprotein 2A (SV2A) radioligand, 11 C-UCB-J PET, a marker of synaptic density (Finnema et al., 2016).”
BackgroundMethodApplication of SV2A PET in neurodegenerative disorders
Chen, D., & JIANG, H. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0086
Quantitative Analysis of the Synaptic Organization of the Human Temporal Lobe Neocortex
Rollenhagen, A., Sätzler, K., & Lübke, J. H. R. (2024) · Neuromethods · doi:10.1007/978-1-0716-4019-7_12 · Cited by 1
Rollenhagen, A., Dastjerdi, A. S., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2024) · eLife · doi:10.7554/elife.99473.1
Bringing “precision” to psychiatry: Challenges and promises
Gogos, J. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-98808-7.00017-5
Chetia, S. (2024) · UPCommons institutional repository (Universitat Politècnica de Catalunya) · doi:10.5821/dissertation-2117-422062
Rollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2025) · eLife · doi:10.7554/elife.99473.2
Chan, D., Spires‐Jones, T. L., Provenzano, F. A., Glennon, E. B. C., & Duff, K. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780190065324.003.0020
Positron Emission Tomography Brain Imaging Methodologies
Hillmer, A. T., Cosgrove, K., & Carson, R. E. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0009
Self-citationGudmundsen, F., Li, Z., Baun, C., Svensson, J. E., Langkjær, N., Palner, M., & Plavén‐Sigray, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.11.642549
“More recently, PET imaging of synaptic vesicle glycoprotein 2A (SV2A) [12–14] has enabled in vivo quantification of synaptic density, providing new opportunities to track synapse loss [15,16], which is a key feature of neurodegeneration [17,18] that correlates strongly with cognitive decline [19].”
Rollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2025) · eLife · doi:10.7554/elife.99473.3
Rollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2025) · eLife · doi:10.7554/elife.99473.4
Fluid and Imaging Markers of Synaptic Injury
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_4
Rollenhagen, A., Sadeghi, A., Walkenfort, B., Hilgetag, C. C., Sätzler, K., & Lübke, J. H. R. (2025) · eLife · doi:10.7554/elife.99473.5.sa3
Moore, M., Katsumi, Y., Iordan, A. D., Dolcos, S. M., & Dolcos, F. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197677131.013.32
Metadata
- Authors
- Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D. D., Mercier, J., Hannestad, J., Huang, Y., & Carson, R. E.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Finnema, Sjoerd J.
- Hannestad, Jonas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-07-20
- Volume
- 8
- Issue
- 348
- Pages
- 348ra96-348ra96
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2503767557
- Cited by
- 575
- References
- 59
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 81 · 2023: 54 · 2022: 92 · 2021: 67 · 2020: 54 · 2019: 43 · 2018: 23 · 2017: 31 · 2016: 6
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swebilius Foundation
- UCB Pharma
- Swedish Research Council
- National Center for Advancing Translational Science (UL1 TR000142)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- synaptic density, SV2A, positron emission tomography, presynaptic terminals, synaptophysin, temporal lobe epilepsy, synaptic loss, Alzheimer's disease, neuroimaging
- MeSH terms
- Adult, Aged, Brain, Epilepsy, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Synapses, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.